Omics Biomarkers in Precision Oncology: From the Lens of the ASCPT Biomarkers and Translational Tools and Oncology Communities
Year: 2026
Type: article
Abstract: Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine. In precision oncology, validating biomarkers is a greater challenge than discovering them. The biomarkers discussed here span a wide evidentiary spectrum, from those endorsed in clinical guidelines to those that remain investigational.
DOI: 10.1111/cts.70712
Institutions: Misr International University, Genentech, Foundation Medicine (United States), Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of California, San Francisco, Nurix (United States), United States Food and Drug Administration, Center for Drug Evaluation and Research
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,630
OpenAlex ID: W7203626122